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Preface 
 
This dissertation is about hereditary hemorrhagic telangiectasia (HHT) associated epistaxis. It 
proposes a new grading system for HHT associated epistaxis, and describes the grade of 
epistaxis and its impact on the quality of life in the Norwegian HHT population. It also 
discusses the early result of a new technique of intranasal injection of bevacizumab in treating 
HHT associated epistaxis.  The results and conclusions of the following publications are 
presented and discussed:  
 
Original articles: 
I. Al-Deen S, Bachmann-Harildstad G. A grading scale for epistaxis in hereditary 
haemorrhagic teleangectasia. Rhinology 2008 Dec;46(4):281-4. 
 
II. Dheyauldeen S, Abdelnoor M, Bachmann-Harildstad G. The natural history of epistaxis 
in patients with hereditary hemorrhagic telangiectasia in the Norwegian population: a 
cross-sectional study. Am J Rhinol Allergy 2011 Jul;25(4):214-8. 
 
III. Geirdal AO, Dheyauldeen S, Bachmann-Harildstad G, Heimdal K. Quality of life in 
patients with hereditary hemorrhagic telangiectasia in Norway: A population based 
study. Am J Med Genet A 2012 Apr 23. 
 
IV. Dheyauldeen S, Ostertun GA, Osnes T, Vartdal LS, Dollner R. Bevacizumab in 
hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection 
protocol based on the vascular anatomy of the nose. Laryngoscope 2012 
Jun;122(6):1210-4. 
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My role in paper III, as a second author, was to measure the epistaxis grade of the included 
patients, according to the grading system proposed in paper I. I have also been involved in 
planning the study design. In addition, I reviewed and updated the clinical manifestation, 
diagnostic criteria and the genotype of the included patients and participated in writing the 
introduction and results of the article and in discussing the results. 
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Abbreviations and acronyms: 
 
ALK1 Activin-receptor-like kinase 1. 
AVF Arteriovenous fistulae. 
AVM  Arteriovenous malformation. 
BP  Bodily pain. 
CL Cantril’s Self-Anchoring Ladder. 
CT Computed tomography. 
CAVM Cerebral arteriovenous malformation. 
CNS Central nervous system. 
ENG Endoglin. 
ESS Epistaxis severity score. 
GH General health. 
GI Gastrointestinal. 
HAVM Hepatic arteriovenous malformation. 
HHT Hereditary hemorrhagic telangiectasia. 
HR-QoL Health related quality of life. 
IFT Intensity, frequency and transfusion epistaxis grading system. 
JPHT Syndrome of juvenile polyposis and HHT. 
MCS Mental component scale. 
MH Mental health. 
MRI Magnetic resonance imaging. 
PAVM Pulmonary arteriovenous malformation. 
PCS Physical component scale. 
PF Physical function. 
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10QoL Quality of life. 
RE Role limitation due to emotional problems. 
RP Role limitation due to physical problems. 
SD  Standard deviation. 
SF Social functioning. 
SF-36 Short form 36. 
SFB-HHT HHT-Symptomspezifischer Fragebogen (German) = HHT-Symptom 
specific questionnaire (English).  
STROBE The strengthening the reporting of observational studies in epidemiology. 
TGFβ-BMP Transforming growth factor beta – bone morphogenic protein.  
VEGF Vascular endothelial growth factor. 
VT Vitality. 
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Chapter 1 
 
1.1 Introduction: 
 
Hereditary hemorrhagic telangiectasia (HHT), also known as Rendu–Osler–Weber disease, is 
a rare, vascular disorder with autosomal dominant inheritance pattern, characterized by 
vascular abnormalities in the form of mucosal and cutaneous telangiectases and arteriovenous 
malformations (AVM). Recurrent bleedings from telangiectases, most commonly in the form 
of epistaxis and less commonly in the form of gastrointestinal (GI) bleedings, are 
characteristic of the disease. Arteriovenous malformations can be found in the lungs, liver, 
and central nervous system (CNS). Life threatening visceral bleedings from AVMs of the 
lung, liver and CNS are also known clinical findings. 
 
1.1.1 Clinical features: 
 
Epistaxis: 
Spontaneous recurrent epistaxis from telangiectases in the nasal mucosa is the most common 
clinical manifestation of HHT (1-4). Nosebleeds are the first clinical symptom of the disease 
in about 80% of cases (5;6). The severity and frequency of epistaxis is highly variable even 
within the same family (1;7).  
 
Mucocutaneous telangiectases: 
Telangiectases of the skin and oral mucous membrane occur in 50-90% of HHT individuals 
(2;5;8-10). It usually presents later in life than epistaxis and increases in size and number with 
age (11). They typically occur in the face, lips, buccal mucosa, tongue, fingertips, hand, ears 
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and chest, but can occur elsewhere (2;5). They may bleed but rarely to a degree of clinical 
significance (2;12). 
 
Gastrointestinal tract: 
Mucosal telangiectases in the GI tract may lead to recurrent upper or lower GI bleeding in 15-
33% of HHT patients (10;11;13). They present with iron deficiency anemia, and occasionally 
with acute GI (2;10). The prevalence of GI telangiectases, including non-symptomatic 
telangiectases, is still doubtful (14;15). Some studies showed a prevalence of 75-86% (16;17). 
 
Liver: 
Asymptomatic hepatic AVM (HAVM) occurs in 30-74% of HHT patients (18-23). 
Symptomatic hepatic involvement is less common (9;23). Symptomatic liver involvement 
includes: high output heart failure secondary to intrahepatic shunt, portal hypertension, biliary 
disease, and portal encephalopathy (21;24-27).  
 
Lung: 
The prevalence of pulmonary arteriovenous malformations (PAVMs) in HHT patients 
depends on the method used for detection and the gene mutation type (28). Based on chest CT 
scan and/or pulmonary angiography, the PAVM can be detected in 26-56% of HHT patients 
(8;9;15;29-32),  with a prevalence of 49-75% among HHT1 subtype and 5-44% among HHT2 
subtype (9;15;29;30). A recent study showed positive intrapulmonary shunt in 85% of HHT1 
patients, and 35% of HHT2 patients using contrast echocardiography, compared to 7% in the 
control population (30).  
Pulmonary arteriovenous malformations lead to hypoxaemia because of the pulmonary right-
to-left shunt effect. The lack of the filtering effect of the pulmonary capillary bed allows small 
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emboli to reach the systemic circulation, particularly the cerebral circulation. In addition, the 
fragile vessels of these AVMs can bleed into the bronchial tree or the pleural cavity (2).  
The other type of lung affection in HHT is the rare pulmonary arterial hypertension which 
occurs predominantly in HHT2 patients (33;34). 
 
Central nervous system (CNS): 
Typical primary HHT related affection of the brain varies from cerebral arteriovenous 
malformations (CAVMs), arteriovenous fistulae (AVFs), microAVMs (measuring <1 cm in 
size) and capillary telangiectases (35;36). These can be found in approximately 23% of HHT 
patients on screening (35). Symptoms associated with these lesions include headache, 
seizures, ischaemia of the surrounding tissue due to a steal effect, or hemorrhage(2).   
Other CNS related clinical manifestations including migraine, brain abscess, transient 
ischemic attack, and stroke are usually complication of PAVM (secondary cerebral affection). 
Pulmonary AVMs are the source of cerebral involvement in 2/3 of the cases in whom 
neurological symptoms develop (37).   
Spinal AVMs are significantly less common than brain AVMs and usually present with 
paralysis and/or complaint of back pain (28). 
 
1.1.2 History: 
 
The word telangiectasia was first used by the ophthalmologist Carl Ferdinand Graefe in 1808 
to describe small vessels anomalies (38;39). The earliest publications of the disease were by 
Sutton in 1864 (40) and Babington in 1865 (41) who described several families with epistaxis 
without using the word “telangiectasia”. Rendu in 1896 described the disease as recurrent 
nosebleed with cutaneous angiomas (42). Osler described in 1901 families with recurrent 
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epistaxis with cutaneous and mucous membrane telangiectases and differentiated the disease 
from hemophilia (43). In 1907, Weber described the disease as hereditary angiomas with 
recurrent epistaxis (44). Hanes (45) described in 1909 for the first time the histopathological 
aspect of the disease, and he is regarded as the forgotten man in Rendu-Osler-Weber disease 
(39;46). In 1994, ENG mutation in chromosome 9 outlined as the cause of HHT type 1 (47). 
ALK1 mutation in chromosome 12 was described as a cause of HHT type 2 in 1996 (48). The 
diagnostic criteria, known as Curaçao Criteria were developed in 1999 and published in 2000 
(49). The criteria were validated and were included in the international guidelines for 
diagnosis and management of HHT in 2009 (34;35;50). Elevated level of VEGF in the serum 
of HHT patients has been described for the first time in 2003 (51). 
   
1.1.3 Epidemiology: 
 
Hereditary hemorrhagic telangiectasia is a rare disease with a prevalence of 1 in 5-8000 
people (52-54). The disease has wide geographical and ethnic distribution (5). 
Although it is an autosomal (non-sex linked) disease, with an expected female to male ratio is 
1:1, most of the studies show a higher female to male ratio (1;3;11;29;55;56). This is most 
likely because of recruitment bias due to the fact that females are usually more oriented to self 
health care than males. Other possible explanations are the chronic blood loss due to 
menstruation or the hormonal factor, which can lead to more obvious symptoms and earlier 
diagnosis in females than males.  
 
1.1.4 Genetics: 
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Hereditary hemorrhagic telangiectasia is an autosomal dominant inherited disease, its 
penetrance increasing with age (57). The affected individuals are heterozygous. Homozygous 
forms are lethal and associated with intrauterine or infantile death (58-60). Mutation at 
Endoglin (ENG) gene in chromosome 9 and mutation at activin-receptor-like kinase 1 (ALK1) 
gene in chromosome 12 are responsible for 90% of the HHT cases (5;57). These two genes 
account for the two types of the disease, which are known as HHT1 and HHT2 respectively. 
A third and forth disease causative loci with still unknown genes have been described in 
chromosome 5 (61) and chromosome 7 (62). Mutation at SMAD4 gene in chromosome 18 
leads to the syndrome of juvenile polyposis and HHT known as JPHT (63). 
 
1.1.5 Pathogenesis: 
 
Telangiectases are small dilated blood vessels near the surface of the skin or mucous 
membranes, measuring between 0.5 and 1 millimeter in diameter. Longitudinal studies, 
investigating the natural course of the telangiectases, do not currently exist. However, it has 
been emphasized that the earliest morphologic change in the pathogenesis of HHT appears to 
be focal dilatation of postcapillary venules. As the venules increase in size, in both luminal 
diameter and vascular wall thickness, they become convoluted and connect to enlarging 
arterioles through capillary segments. Eventually these segments disappear, leading to direct 
arteriovenous communication. In telangiectasis, most venules show excessive layers of 
smooth muscle cells without any elastic fibers or have an incomplete layer of smooth muscle 
cells. Similar to telangiectases, AVMs lack capillaries and consist of direct connections 
between arteries and veins, but are much larger in size (5;64). 
Both ENG and ALK1 genes encode proteins involved in signaling by the transforming growth 
factor beta – bone morphogenic protein (TGFβ-BMP) super-family in the vascular endothelial 
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cells (5;7). TGFβ-BMP regulates cellular growth, differentiation and wound repair through 
signal transduction cascades from transmembrane receptor complexes (5). The abnormal 
vessels in HHT develop because of abnormal TGFβ-BMP signaling during vascular 
development and homoeostasis (2;5;34;65). This leads to the persistence of the activation 
phase of angiogenesis where angiogenic factors, such as the vascular endothelial growth 
factor (VEGF), are produced and play a potential role in angiodysplasia (65). 
 
1.1.6 Diagnosis: 
 
There are no biochemical tests for HHT and the diagnosis is clinical and depends on four 
diagnostic criteria, known as Curaçao Criteria, which were developed in 1999 (49) (Table 1). 
The Curaçao criteria were validated in 2009 (35;50). According to these criteria, a person is 
diagnosed with “definite HHT” when having three or four criteria; “suspected HHT” when 
having two criteria and “unlikely HHT” when only one criterion is present. 
Genetic tests for ENG, ALK1 and SMAD4 genes are available. They are used to clarify the 
specific HHT mutation in an HHT family, allowing diagnosis among those relatives (often 
children and young adults) who do not meet clinical diagnostic criteria (34;35). The genetic 
tests are negative in 15-20% of HHT families (8;49;66).  
 
1.1.7 Screening: 
 
Screening in HHT refers to testing members of HHT families (who may or may not be 
symptomatic for other aspects of the disease) for the presence of silent disease manifestations 
such as pulmonary, hepatic or cerebral AVMs (34).  
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Screening for pulmonary, hepatic and cerebral AVMs are recommended according to the 
international guidelines (35). 
Pulmonary screening has been recommended for all patients with possible or confirmed HHT 
(12;35;67;68). The recommended initial screening test for PAVM is transthoracic contrast 
echocardiography. Positive screening should be confirmed with unenhanced multidetector 
thoracic CT scan with thin-cut (e.g. 1-2mm) reconstructions (35).  
Screening for hepatic AVM are recommended to clarify the diagnosis of HHT using Doppler 
Ultrasound, in patients with 1 or 2 HHT diagnostic criteria and in whom genetic testing is 
either inconclusive or unavailable. The international guidelines also recommend screening for 
cerebral AVMs by cerebral MRI (35).  
Children of a parent with HHT who do not meet the diagnostic criteria should be considered 
to have the disease for purposes of screening unless excluded by genetic test (35;69). 
 
1.1.8 Treatment: 
 
Correcting the gene defect in ENG, ALK1 or SMAD4 by gene therapy is not yet available.  
The applicable therapies now can be summarized in four groups:  
1. Compensation therapy: to compensate for blood loss by repeated red packed cell 
transfusions and iron supplements. 
2. Obliteration or removal of the affected vessels: this includes embolization therapy for 
pulmonary and cerebral AVMs and feeding arteries for nasal mucosa. This therapy 
category includes also the surgical resection of the cerebral AVM, replace the nasal 
septum mucosa by skin (septodermoplasty) and laser therapy for telangiectases.  It 
includes also organ (liver) transplantation (70;71). 
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3. Prevention of excessive bleeding by the use of prothrombotic therapy as 
antifibrinolytic (e.g. tranexamic acid) (72) or hormonal therapy (e.g. Tamoxifen and 
Raloxifin) (73).  
4. Revise or correct the abnormal vascular response by anti-angiogenesis (Bevacizumab) 
(74), or molecules stimulating vessel maturation (Thalidomide) (75). 
 
1.1.9 Prognosis: 
 
Hereditary hemorrhagic telangiectasia is associated with a shorter life expectancy and early 
mortality. Although maternal complication can lead to death of young women at childbirth 
due to hemorrhage from pulmonary or cerebral AVMs in a few cases (14;54), a statistically 
significant difference in the life expectancy between gender and gene mutation subgroups of 
the disease has not been demonstrated (54;76).  
The decrease in life expectancy can approach 7 years (76). This early mortality is usually due 
to major acute complications (54;76). 
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Chapter 2: 
 
2.1 Background 
 
2.1.1 HHT associated epistaxis: 
 
Epistaxis is usually the first and most common symptom in HHT. Eighty to 100 percent of the 
HHT patients suffered from epistaxis (6;11;29;31). Epistaxis is the first symptom of the 
disease in about 80-90% of the patients (3;5). The majority of the patients start to experience 
recurrent nosebleed during the first two decades of life (1;3;11;56).  Although AVMs are the 
most life threatening pathologies for patients with HHT, epistaxis is the most annoying 
symptom. It has the greatest negative impact on health-related Quality of Life (QoL) (4;77-
79). Hereditary hemorrhagic telangiectasia associated epistaxis is characterized by being 
recurrent, spontaneous or easily provoked by bending over, sneezing, running or emotional 
stress (1;2;7). The HHT associated epistaxis can be functionally and socially debilitating for 
the patient (80), it can affect almost all aspects of life and lead to secondary health problems 
like iron deficiency anemia, shortness of breath and malaise (3). 
 
2.1.2  The severity of HHT associated epistaxis: 
 
The clinical features of HHT, including epistaxis severity, are highly variable, show ethnic 
and geographical variations (81), and vary even among members of the same family (7). 
Seasonal and diurnal variations of epistaxis associated with HHT have been described (82). 
Different systems have been used to score HHT associated epistaxis (83). Recently, an 
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epistaxis severity score (ESS) was proposed, sponsored by the HHT Foundation International 
(84). There is still no common internationally accepted grading system for epistaxis in HHT. 
 
2.1.3 Treatment of HHT associated epistaxis: 
 
A wide variety of treatment options have been developed for control of epistaxis in HHT (78) 
(Table 3). Many of these modalities are expensive and almost all of them have side effects, 
drawbacks and limitations. Choosing the appropriate modality for each patient depends 
extensively on the severity of the epistaxis.  
 
2.1.4 HHT in Norway: 
 
The HHT team at Oslo University Hospital - Rikshospitalet is a multidisciplinary working 
group representing the only “HHT center of excellence” in Norway. It aims to improve the 
diagnosis, treatment and follow-up procedures for patients with HHT in Norway. The team 
represents collaboration between the Department of Medical Genetics, Department of 
Otorhinolaryngology, Department of Pulmonary Medicine, Gastroenterology Department, 
Radiology Department, Department of Neurosurgery, Department of Dermatology, 
Department of Blood Diseases and Center for Rare Disorders. The team meets regularly to 
discuss treatment and research projects on HHT.  
Patients with clinical suspicion of HHT are referred to the team from all over the country. 
These are usually patients with recurrent epistaxis, newly diagnosed AVMs, patients with GI 
bleeding in whom the endoscopic examination revealed GI telangiectases or asymptomatic 
relatives of HHT patients.  
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In 2006, the HHT patients’ database was established for quality assurance and research. In 
December 2011 there were 250 patients registered in the database. Included in the database 
are patients with definite clinical diagnosis (with 3-4 diagnostic criteria), patients with 
unlikely or suspected clinical diagnosis (with 1-2 diagnostic criteria) with a positive ENG, 
ALK1 or SMAD4 gene mutation test, and asymptomatic first degree relatives with a positive 
ENG or ALK1 gene mutation test.   
 
2.2. Purpose of thesis: 
 
Effectiveness of treatment of HHT associated epistaxis depends on choosing the appropriate 
treatment modality for each patient. This in turn depends on the severity of epistaxis in each 
patient, its impact on QoL, and co-morbidity.  In this dissertation, a grading system for HHT 
associated epistaxis is proposed and the natural history of epistaxis and its impact on QoL was 
investigated. A second objective was to study the effectiveness of a new treatment modality in 
the treatment of HHT associated epistaxis.  The necessity of this work came from: 
1. Different institutions are using different treatment modalities and different grading 
systems for the severity of epistaxis in HHT (78;85-87). This makes it difficult to 
compare and evaluate the effectiveness of different treatment modalities in treating 
epistaxis of different grades. The aim was therefore to propose a grading system that 
can be the base for an internationally accepted system. 
2. Understanding the natural history of epistaxis in HHT is important to predict who the 
high-risk patients are and to prevent complications. Most of the studies focus on the 
treatment modalities of the disease. Few studies highlight the natural history of HHT 
associated epistaxis, and most of these studies (1;11;46;55;56;87-89) were performed 
before the approval of the Curaçao diagnostic criteria. The natural history of HHT 
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associated epistaxis in the Norwegian population has not been studied before. The aim 
was to study the natural history of HHT associated epistaxis in the Norwegian 
population and to compare the results with studies from populations in other countries. 
3. The impact of HHT associated epistaxis on QoL has a role in treatment decision. This 
impact has been studied in the United Kingdom (4;77-79), Germany (90;91), Greece 
(92) and Italy (79) but not in Norway. The aim was to study the impact of HHT 
associated epistaxis on QoL in the Norwegian population as a cross sectional study. 
The results of this study can be used in the future as a base-line to evaluate the 
effectiveness of new treatments. 
4. The recent advance in understanding of the molecular base of the HHT pathogenesis 
opened the door for new possible medical therapies of the disease. The most recent of 
these therapies is bevacizumab (75;93). This study presents our early experience in 
using bevacizumab as intranasal injection in treating HHT associated epistaxis.  
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Chapter 3: 
 
3.1 Aims of the study: 
 
3.1.1 Paper I 
The aim of paper I was to find a grading system for HHT associated epistaxis, which may 
serve as a proposal for an internationally accepted system. The aimed system is essential for 
better comparison of the results of different research groups. It is also important to judge the 
effectiveness of different treatment modalities used by different centers.   
 
3.1.2 Paper II 
The aim of paper II was to study the natural history of HHT associated epistaxis in the 
Norwegian population in relation to gender, age, gene mutation, age of onset of epistaxis and 
effect of treatment. This was important for the following purposes: 
1. Better understanding of the natural history of HHT associated epistaxis generally. 
2. The result of this cross sectional study might be the base for a future longitudinal 
study. 
3. To compare the severity of epistaxis in the Norwegian population with populations in 
other countries. 
4. The results of this study can be used as a base-line for future researches concerning 
HHT associated QoL and the efficacy of different treatment modalities in treating 
HHT associated epistaxis. 
   
3.1.3 Paper III 
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The aim of paper III was to assess QoL in HHT patients in Norway by analyzing different 
levels of QoL: overall-, health-related and disease-specific QoL, taking into account 
demographic- and clinical variables. The reason for looking for all three levels of QoL was to 
examine how the HHT patients subjectively experienced overall and disease specific QoL, 
and how QoL is compared to normative population, using a generic health-related QoL 
measure.  
 
3.1.4 Paper IV 
Paper IV aimed to introduce and evaluate the effectiveness of a new method of intranasal 
bevacizumab injection in treating HHT associated epistaxis, based on the nasal vascular 
anatomy. The effect of local bevacizumab on epistaxis was measured using the IFT and the 
ESS grading systems. 
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Chapter 4: 
 
4.1 Materials and methods 
 
4.1.1 Materials 
 
4.1.1.1 Paper I 
The materials of the first paper were the main four different grading systems which had been 
used in different studies, the opinions of experts in the field of rhinology, and our experience 
in treating and follow up HHT patients at the Department of Otorhinolaryngology, Head and 
Neck Surgery in Oslo University Hospital-Rikshospitalet.  
 
4.1.1.2 Paper II 
One hundred and sixty patients have been included in the HHT research data base at HHT 
center at Oslo University Hospital / Rikshospitalet. One hundred and nine patients fulfilled 
three or four Curaçao criteria by the 1st of January 2009. Eleven patients were excluded 
because they were unavailable for follow up. Ninety-eight patients were contacted during the 
period from 01.01.2007 to 30.06.2009 either by direct consultation or telephone interview. 
The total group of patients (n=98) was divided into two subgroups: “the untreated group” 
(n=47) which included patients who had not been treated for epistaxis locally in the nose 
during the last 2 years and were not operated with septodermoplasty previously and “the 
treated group” (n=51) which included patients who were surgically treated for epistaxis with 
pulsed dye laser, diode laser, argon plasma coagulation, electro- or chemo-cauterization, 
septodermoplasty or a combination of these treatment modalities, during the last two years.  
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As it is a cross sectional study, the STROBE statement (94) recommendations have been 
followed. 
 
4.1.1.3 Paper III 
The patients: included patients were those with ENG or ALK1 mutation and/ or having three 
or more Curaçao criteria for HHT, and older than 16 years at the time of genetic counseling. 
All included patients had given a written informed consent. 
Ninety-five patients with HHT were invited to participate in the study. Sixty-six patients 
responded (response rate 71%) comprised of 39 women and 27 men. 
Normative sample: 990 individuals of the 3648 individuals, who were included in Survey of 
Level of Living by Statistic Norway which had been carried out in 2002, were randomly 
drawn matching the age and gender of the patients group (15 controls per HHT patient). 
 
4.1.1.4 Paper IV 
The IFT grade of all patients, who had been treated for their HHT associated epistaxis during 
the last three years prior to this study, was recorded before each treatment. These treatments 
included: pulsed dye laser, diode laser or argon plasma coagulation. Many of these patients 
have been treated and followed up in our department for a much longer period of time but the 
IFT grading was available only for the last three years. The indications for inclusion in this 
study were clinical. The most common indication was the lack of clinical benefit, on the level 
of IFT grading, during the last 2-3 years in spite of increasing the frequency of the laser 
therapy, and additional medical therapy (Table 5).  
Eight patients, with definite HHT diagnosis according to Curaçao diagnostic criteria, were 
included in the study. Five of the eight patients were females. The mean age was 56.5 years 
(SD =12.7, range 36 – 71). All patients had been previously treated for their HHT associated 
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epistaxis, with repeated pulsed-dye laser, diode laser, or argon plasma cauterization. 
Additional medical therapy, like oral and topical tranexamic acid, oral tamoxifen or raloxifen, 
and topical estrogen, were tried (Table 5). One of the patients was previously operated with 
septodermoplasty. Seven of the patients needed oral or intravenous iron supplement. Two of 
the included patients had nasal septum perforation from before.  
Three out of the eight patients complained of HHT related gastrointestinal bleeding, three had 
pulmonary AVMs, one patient had HHT related pulmonary hypertension with cardiac 
complication, and another one had hepatic AVM, one patient complained of intractable 
migraine without pulmonary or cerebral AVMs (Table 5). 
 
4.1.2 Methods 
 
4.1.2.1 Paper I 
The literature has been searched for in Pub-Med, using the following keywords: Epistaxis, 
epistaxis AND grading system, epistaxis AND classification, epistaxis AND Osler disease, 
epistaxis AND hereditary haemorrhagic teleangiectasia.  
A questionnaire with five questions, concerning the characteristics of an epistaxis grading 
system (Appendix 2), was sent by e-mail to 22 international medical professionals, who have 
published papers in the field of rhinology or HHT. The questionnaire was sent to experts in 
the following countries: Denmark, France, Germany, Iraq, Italy, Japan, Norway, Spain, UK, 
and USA. One reminder was sent to those experts who had not replied within four weeks. 
Comparisons were made between the existing systems and experts’ opinions. In case of 
discrepancy between the experts’ opinion and the existing grading systems, the decision was 
made in favor of the experts’ opinion. In case of discrepancy among experts’ opinions also, 
we chose the criterion, which we believed that was more appropriate.  
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Using this as basis, the final version of the aimed grading system was shaped by own 
experience. 
 
4.1.2.2 Paper II 
The grade of epistaxis was obtained by recording the intensity, the frequency and the amount 
of blood transfusion during the period of the last four weeks before the date of consultation or 
the telephone interview (Table 2). The grading had been converted into a single scale by 
multiplying the intensity (I) by the frequency (F), adding blood transfusion (T). Zero had been 
referred as “No bleeding”, 1-5 as “Mild”, 6-10 as “Moderate”, 11-15 as “Severe”, 16 and 
more as “Intractable”.  
The grading of epistaxis of the untreated group was obtained by telephone interview.   
All patients were genetically tested for ENG and ALK1 gene mutation. All patients were asked 
about the age of onset of spontaneous recurrent epistaxis. 
Statistical analysis: Association of epistaxis grade with age, gender, gene mutation, and age 
of onset of epistaxis was calculated using the contingency of chi-square tables and Fisher’s 
exact test. Spearman’s rank correlation was performed between age of onset of epistaxis and 
the grade of epistaxis. A power analysis was performed for the outcome gender and the grades 
of epistaxis, and between the outcome age of the patients and the grades of epistaxis. 
In addition, the association of epistaxis frequency (F) and epistaxis severity (I) with age, 
gender, gene mutation, and age of onset of epistaxis was also calculated using the contingency 
of chi-square tables (these data was not published in paper II). 
 
4.1.2.3 Paper III 
Demographic and HHT disease-related information 
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The questionnaire registered demographic and HHT related information. The demographic 
variables included age, level of education, marital status, and work status. 
HHT related information was based on the Symptom-specific questionnaire in HHT patients 
(SFB-HHT) (91) (Appendix4). This questionnaire contained items like: duration since the 
start of the first manifestation, age of onset, mutation type and Curaçao criteria. In addition 
this questionnaire contained items about the nosebleeds like: if nose bleedings had more 
impact on daily life than other manifestations; nose bleedings impact on participation in daily 
working and other social life; time used on nose care per day, and intensity and frequency of 
epistaxis. Discomfort due to treatment of nose bleedings and the number of treatments in local 
anesthesia last year were also registered. Patients were asked if they had pain in relation to 
HHT, with response options: yes / no. In addition, they had been asked (if the answer was 
yes) what kind of pain they had. The kinds of pain reported were: headache, pain in the 
abdomen and nose or nasal region, pain related to treatment and general pain in the body 
(unpublished data). 
 
Quality of life  
QoL was assessed in three levels: 
1. Overall QoL using Cantril’s Self-Anchoring Ladder (CL), which is a self-administered 
questionnaire with one question: “How is your life?” The response alternatives are 0 -
10 (0 = worst QoL, 10 = best QoL). 
2. Short Form 36 (SF-36) (95;96), which measures eight dimensions: physical 
functioning (PF), role limitation due to physical health problems (RP), bodily pain 
(BP), general health (GH), vitality (VT), social functioning (SF), role limitations due 
to emotional problems (RE), and mental health (MH). Physical component scale 
(PCS) and Mental component scale (MCS) are constructed on the basis of the items 
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from these dimensions. VT, SF, RE, and MH contribute to MCS, while PF, RP, BP, 
and GH do so for PCS. 
According to standard (SF-36) scoring, all scores were transformed into a 0 (worst) to 
100 (best) scales. Score <40% was regarded as poor QoL (97).  
3.  Disease-specific quality of life questionnaire in HHT patients (SFB-HHT-Q, 
Appendix 4): using the following question: “To which level does the disease impact 
your Quality of life?” The answer alternatives are from 1 which corresponds to ‘‘no 
impact on QoL’’ and to 10 which corresponds to ‘‘the worst possible QoL’’. A cut-off 
score was chosen at 6 or lower (1–6 score corresponds to no or small impact on QoL) 
Higher score of SF-36 and (CL) reflect better QoL, while higher SFB-HHT score indicating 
that the disease has more impact on the QoL. 
Statistical analyses: Categorical variables were analyzed with chi-square tests. Quality of life 
measures were analyzed using independent sample T-test.  
Hierarchical multiple regression analyses were used to examine possible associations between 
demographic and HHT disease related variables as independent variables, and different QoL 
scores as dependent variables.  
 
4.1.2.4 Paper IV 
To evaluate the effect of the intranasal bevacizumab therapy, the grades of epistaxis were 
recorded by using IFT grading and the ESS system. The grades were recorded immediately 
before the treatment by direct interview and monthly after the treatment by telephone 
interviews. In addition, hemoglobin levels were measured immediately before and monthly 
after the treatment. Quality of life was evaluated before and four weeks after the procedure by 
health related quality of life questionnaire (HR-QoL) SF-36. In addition, overall QoL was 
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evaluated by Cantril`s Self-Anchoring Ladder (CL) and the disease specific QoL was 
evaluated by SFB-HHT-Q. The patients themselves filled these questionnaires.     
The injection procedure was done in local anesthesia with light sedation in 7 out of the 8 
patients. A total dose of 100 mg bevacizumab was injected submucosally. Each of the 
following areas was injected with 0.5 ml bevacizumab on each side:  
1. The sphenopalatine area.  
2. Upper part of bony septum. 
3. Upper part of the lateral nasal wall. 
4. The anterior floor of the nose.  
These four areas correspond to the points of entry of the main arteries responsible for the 
blood supply of the nasal mucosa, which are: the sphenopalatine artery, the anterior ethmoid 
artery, the posterior ethmoid artery and the greater palatine artery (Figure 1 in paper IV). 
The procedure was endoscopically assisted, using 0° and/or 30° rigid nasal fibro-optic scope. 
No cauterizations or laser photocoagulation were done during or after the procedure.  
Statistical measures: 
Paired sample t-test was used to compare the difference between pre- and post- treatment 
parameters. SPSS version 18 was used for the statistical calculation.  
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Chapter 5: 
5.1 Results 
5.1.1 Paper I 
In the literature, four different grading systems have been applied for the grading of HHT 
associated epistaxis (Appendix 1).  
The first one (78) depends on a disease-specific questionnaire assessing the severity and 
frequency of bleeding using a visual analogue scale and information regarding other 
treatments such as blood transfusion. In addition the QoL has been taken into consideration. 
The epistaxis was graded into: mild, moderate and severe. The second grading system 
categorized the grade of HHT associated epistaxis into mild, moderate and severe (6;87). It 
used the frequency and duration of bleeding as one item, and the need of blood transfusion as 
another item and merged these two items in one scale (single multi-item scale). A forth grade 
(intractable bleeding) has sometimes been used in this system (87). The third system was a 
two scales system in which the severity (intensity) of bleedings was taken as one scale, graded 
into three grades from 1 to 3 while frequency of bleeding was taken as another scale, graded 
into other three grades from 1 to 3 (82;85). The fourth system graded the epistaxis according 
to the need of blood transfusion, the frequency and the duration of bleeding episodes (98). 
The response rate of the questionnaire from the experts was 45%. Half of the experts preferred 
a “single multi-item scale”, while the others preferred more than one scale. Sixty percent 
chose the absolute scale. Seventy percent answered that blood transfusion is an important 
parameter. All of them (100%) wanted the system to be easy to understand for the patient. 
Ninety percent wanted the system to focus on a definite time period, while 10% wanted it to 
focus on a single bleeding episode.    
 
5.1.2 Paper II 
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Ninety-eight patients were included. The female : male ratio in the total group was 1.9:1. The age 
ranged between 10-90 years (mean: 51, SD =16). Fifty-seven percent of the patients had mild 
epistaxis, 33% moderate, 5% severe, 2% intractable, and 3% did not complain of epistaxis at 
the time of running this study. Forty-four percent of females suffered moderate, severe or 
intractable grade of epistaxis, in contrast to 32% of males. This difference was not statistically 
significant. Considering 10% difference between females and males, for a power of 80% with 
a female : male ratio of 2, the total sample needed would be 883 patients (294 males and 589 
females). There were no statistically significant associations between the frequency (F) or the 
intensity (I) of the epistaxis and the gender (unpublished data). 
Epistaxis in patients less than 30 years old was mild to moderate. Severe grade of epistaxis 
was seen only after the age of 30 years and intractable epistaxis was not observed before the 
age of 50 years. The percentages of more severe grades of epistaxis increased slightly with 
age. None of the patients under the age of 30 years reported a daily bleeding. Daily epistaxis 
was reported only among patients over 30 years old. Similarly, high intensities of epistaxis (I 
>2) were seen only after the age of 20 years (unpublished data). These findings suggested that 
HHT associated epistaxis is progressive with age; however, none of these findings were 
statistically significant. 
Six patients showed neither ALK1 nor ENG mutation. Fifty-five patients had ALK1 mutation 
and 37 patients had ENG mutation. All the non-ALK1, non-ENG suffered mild grades of 
epistaxis. Intractable epistaxis was seen only in the ENG mutation group (2 patients). Four of 
the five patients who suffered severe grade of epistaxis, carried ENG mutation. There was no 
statistically significant difference in the grade, frequency or intensity of epistaxis between 
ENG and ALK1 subgroups. When comparing the grade of epistaxis in the ALK1 subgroup 
with the non ENG, non ALK1 subgroup, and the ENG subgroup with the non ENG, non ALK1 
subgroup separately, a statistically significant difference was found: patients within the non 
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ENG, non ALK1 group showed significant lower epistaxis grades when compared to patients 
with HHT1 or HHT2 (P=0.04).  
Eight of the 98 patients were not sure about the age of onset of epistaxis. The age of onset of 
epistaxis ranged from 1- 52 years with a mean of 15.7 (SD =14). In 56% of the patients the 
onset of epistaxis occurred by or before the age of 10 years, and in 77% the onset was by or 
before the age of 20 years. The latest onset of spontaneous epistaxis was at the age of 52 
years.  
The two patients with intractable grades of epistaxis started epistaxis before the age of 10 
years and both of them carried ENG mutation. Four of the five patients who suffered severe 
grades of epistaxis started epistaxis by or before the age of 20 years and all the four carried 
ENG mutation. One of the five patients with severe grade of epistaxis started epistaxis late (by 
the age of 50 years), and this patient was the only one in the severe grade group who carried 
ALK1 mutation. There was no statistically significant correlation between the age of onset 
groups of epistaxis and the grade, frequency or intensity of epistaxis. However, 32/35 (91%) 
of the HHT1 subgroup and 32/49 (65%) of the HHT2 subgroup had age of onset by or before 
the age of 20 years. This difference was statistically significant (P=0.01, unpublished data). 
The treated group consisted of 51 patients (53%). The distributions of the epistaxis grade, 
epistaxis frequency (F), and epistaxis intensity (I) in the treated and untreated groups were 
quite similar and there was no statistically significant difference. 
 
5.1.3 Paper III 
Sixty-six patients were included, 39 women and 27 men. 
Demographics and HHT/disease-related variables 
No significant differences were found between the HHT group and the normative sample on 
any of the demographic variables. All the responders met the clinical criteria for HHT based 
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on the Curaçao criteria and/or had an ENG or ALK1 mutation. Six responders met the clinical 
criteria for HHT only. Mean age of onset of epistaxis was 15.4 years (SD = 16.2), while the 
mean duration of the disease was 14.6 years (SD = 15.0).   
All patients reported frequent nose bleeds which affect their participation in employment 
more than all other arenas of their everyday lives. While some responders defined their 
nosebleeds as excessive, others described theirs as little or moderate. However, all responders 
reported devoting time on a daily basis to nose-care due to bleeding. Pain and discomfort, due 
to the nose bleeds and/or laser treatments or nose packing, was reported. Most of the 
respondents reported having been treated once or more times with local anesthesia during the 
previous year. 
 
Overall Quality of life  
Seventy-seven percent of the patients reported high level of overall QoL based on the cut-off 
score of 6. A higher number of Curaçao criteria and pain showed differences to a significant 
level, with P<0.001 for both variables. 
 
Health-related quality of life (SF-36) 
Mean score: the mean scores of SF-36 domains ranged from 50.2 to 80.5 with MCS (50.5 
±9.3) and PCS (44.3 ±10.4).  
Comparison with the normative sample: When comparing the HHT group with normative 
sample, the mean scores for all scales of the SF-36, except for BP, were significantly lower in 
the HHT group including MCS and PCS.  
Demographic variables: the mean scores of PF and PCS were significantly higher among 
those having higher levels of education. PF, BP, GH, RE, and PCS showed lower scores to a 
significant level for unemployed patients. There were no significant differences between 
genders in SF-36, except for BP. 
 36 
HHT-disease-related variables: significant differences in HR-QoL were found in time used 
on nose care, intensity of epistaxis, Curaçao criteria (number of manifestations), and 
discomfort due to epistaxis. Frequency of nose bleedings was found to be significantly 
associated with poorer QoL in RE. Time since diagnosis showed a significant association with 
poorer PCS. No significant differences were found between ALK1 and ENG mutation groups. 
Having HHT related pain was associated with significantly poorer level of all aspects of HR-
QoL. On the other hand, comparing the HR-QoL of the 51 patients who did not report having 
HHT related pain, with the normative sample, showed that this patient group has a 
significantly better BP than normative sample, but poorer RP, GH, VT, RE and MCS 
(unpublished data).  
 
Disease specific QoL, SFB-HHT –Q 
Fifty-eight percent of the included patients reported that disease-related QoL was negatively 
associated with HHT. Among HHT disease-related variables, more time used on nose-care, 
intensity of nosebleeds, and pain were associated with poorer disease-related QoL as 
measured by SFB-HHT-Q.  
 
Multivariable hierarchical linear regression analyses 
HHT disease related variables were significantly associated with overall quality of life (CL), 
and explained 30% of the variance in overall quality of life. Among the HHT disease related 
variables, Curaçao criteria had the strongest unique contribution.  
Demographic and HHT disease-related variables were both associated with MCS 
significantly. HHT disease-related variables explained 16% of the variance in MCS, with pain 
and being tired as the factors making statistical significant unique. Altogether, the 
multivariable hierarchical model explained 35% of the variance in MCS. 
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The multivariable hierarchical model explained 68% of the variance in PCS. The HHT 
disease-related variables contributed significantly to the final steps with 52% of the variance 
of PCS. Only HHT disease-related variables contributed significantly to the final model. Pain 
had the strongest associations with physical quality of life.  
According to the disease specific quality of life (SFB-HHT-Q), HHT disease related variables 
contributed significantly to the final model. The multivariable hierarchical model explained 
37% of the variance in disease specific quality of life, and time used to nose care per day had 
the strongest association with SFB-HHT-Q.  
 
5.1.4 Paper IV 
The effectiveness of the intra nasal bevacizumab injection was evaluated firstly four weeks 
after the first treatment. Three of the eight patients did not respond to the bevacizumab 
injection and two of these three received additional injections, of the same dose, four weeks 
after the first dose.  
The mean time from the first bevacizumab treatment until the last epistaxis severity 
evaluation was 9.5 weeks (range = 8 – 12, SD = 1.4). The mean pre-therapy IFT epistaxis 
grade was 14.3 (range = 7 – 25, SD = 7.0). The mean post-therapy IFT epistaxis grade was 3.5 
(range = 2 – 7, SD = 1.6). The difference between pretreatment and posttreatment IFT grading 
was statistically significant (P = 0.007). The mean pre-therapy intensity (I) was 5.1 (range = 3 
– 7, SD = 1.3). The mean post-therapy intensity (I) was 1.9 (range = 1 – 3, SD = 1). This 
difference was significant (P = 0.02). The mean pre-therapy frequency (F) was 4.9 (range = 4 
– 6, SD = 0.6). The mean post-therapy frequency (F) was 3.1 (range = 1 – 6, SD = 1.5). This 
difference was significant (P = 0.01) (Table 7). 
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The mean pretreatment ESS was 6.0 (range = 4.70 – 8.25, SD = 1.21).  Post-therapy ESS 
average was 2.82 (range =1.96 – 4.98, SD = 0.92). This difference in ESS was statistically 
significant (P = 0.001).  
The mean pretreatment hemoglobin level was 10.6 g/dl (range 8.4 – 13.2, SD = 1.6). The 
mean posttreatment hemoglobin level was 13 g/dl (range 8.0 – 17.1, SD = 2.8), (P = 0.01). 
None of the patients received blood transfusion after the treatment. No changes had been done 
to the dose of iron supplement therapy after the treatment except for patient number 6, in 
whom the family doctor discontinued the iron supplement four weeks after the treatment 
because of the dramatic and rapid improvement in the hemoglobin level.  
The effect of the therapy on HR-QoL, measured by SF-36, showed improvements in all SF-36 
dimensions except bodily pain (BP). These improvements were not statistically significant. As 
well, there was an improvement in the mean of overall QoL score and the disease specific 
QoL. These improvements did not however reach statistical significance. 
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Chapter 6 
 
6.1 Discussion: 
 
6.1.1 Purpose of the work 
In this work HHT associated epistaxis has been studied from different aspects. Paper I 
focused on grading systems of HHT associated epistaxis. We discussed, in this paper, the 
importance of having a common internationally accepted grading system, and assessed the 
different systems that had been used at the time of conducting the study. Finally, the IFT 
grading was designed as a proposal for an internationally accepted system. In paper II, the 
grades of HHT associated epistaxis in the Norwegian population was described from diverse 
aspects using the IFT grading system proposed in paper I. It is the first work that studies the 
HHT associated epistaxis in Norway and may serve as a base line for further studies. It added 
more knowledge about the natural history of HHT associated epistaxis generally and made it 
possible to compare the HHT population in Norway with HHT population in other countries. 
The ESS grading system, which was proposed by Hoag et al. (84) for the International HHT 
foundation in 2010, has been discussed in detail in this paper. 
Paper III described the impact of HHT manifestations generally and HHT associated epistaxis 
particularly on different levels and aspects of QoL in the Norwegian HHT population.   
In paper IV, we discussed our experiences with bevacizumab as a new treatment option for 
HHT and presented the application of the IFT grading and the ESS systems. 
 
6.1.2 Grading of HHT associated epistaxis.  
Paper I depended on three sources of knowledge. The first one was the main four grading 
systems from the literature, which were in use at the time of running the study; the second 
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source was medical experts’ opinions; and the third source was our experience in treating and 
follow up HHT patients at the Department of Otorhinolaryngology, Head and Neck Surgery in 
Oslo University Hospital / Rikshospitalet. The four grading systems were evaluated in five 
aspects: 
1. The type of grading scale. 
2. Whether they were relative (without end point) or absolute scales (take at least one 
end point, as zero, in consideration). 
3. Whether blood transfusion was taken as a factor in the grading. 
4. Whether a definite time period was included as a factor in the definition of the scale. 
5. Whether the grading system was easy to understand for the patients. 
Experts’ opinions about these five aspects were collected using a questionnaire. Five 
questions corresponding to these five aspects were sent to 22 international medical experts, 
who have published results in rhinology or HHT. Ten of the experts responded. This response 
rate of 45% was low. A possible explanation of the low response rate is that the questionnaire 
was sent by e-mail and in this way it is impossible to be sure that all the e-mails have been 
received. Telephone call might be a better way to collect the experts’ opinions. Nevertheless, 
the low response rate might be a cause of bias. 
By comparing the existing systems and the experts’ opinions we found that all the existing 
systems are easy to understand and to use by the patients. The exception might be the system 
used by Lund et al (78) which need an additional QoL questionnaire. Similarly all the asked 
experts wanted the system to be easy to understand for the patients. Therefore, we concluded 
that the aimed system should be easy to comprehend for the patients. 
The existing systems either do not focus on a definite observation period or the observation 
period is not a fixed period but varied (week, day or lifetime) from one grade to the other in 
the same system. On the contrary, 90% of the experts wanted the system to focus on a definite 
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time period. In addition, having a definite time period of observation makes the system more 
appropriate to be used both in cross sectional and longitudinal follow up studies. Therefore, 
we concluded that the aimed system should focus on a definite time period of observation. We 
chose a four weeks period of observation, considering the chronicity of HHT and the known 
fluctuating character in severity of HHT associated epistaxis. A shorter period may not be 
representative of the actual epistaxis severity, and a longer period will increase the recall bias, 
as the patient usually will not remember how the situation was for more than four weeks ago. 
Although HHT patients may need blood transfusion due to GI tract bleeding and not only 
epistaxis, blood transfusion is taken as a factor in three of the four existing grading systems. 
Seventy percent of the experts regarded the need of blood transfusion as an important 
parameter in assessing the severity of HHT associated epistaxis. For this reason, we found it 
necessary for the aimed grading system to include the need of blood transfusion as a 
parameter.    
There was no clear tendency among experts’ opinions or among the existing systems towards 
a “single multi-item scale” or “multi-scale system”. Two of the four systems are multi-scale 
systems, while the other two are single multi-item scale (Appendix 1). Similarly halve the 
experts preferred a “single multi-item scale”, while the other halve preferred more than one 
scale. On the other hand, at least in two of the four systems the frequency and the intensity (or 
severity) of the bleeding are used as two separate parameters. In one system the frequency and 
the duration of the bleeding are used as two separate parameters. As mentioned above, we 
found the need of blood transfusion necessary to be encountered in the aimed system as a 
parameter also. Therefore the aimed system should consist of multiple scales, as the 
frequency, intensity and blood transfusion. We chose the intensity rather than the duration 
because two of the existing systems use intensity and only one uses the duration. However, 
since halve the experts wanted a single scale system, we concluded that the aimed system 
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should be easy to be converted to a single scale system. We believe that both the “multi-scale” 
and “single-scale” systems have advantages. The multi-scale system gives the possibility to 
follow changes in the frequency and the intensity of the epistaxis separately, and the single-
scale system (grading the epistaxis as mild, moderate, severe…etc.), is also desired especially 
in the daily clinical work.   
All the existing systems are relative systems without an end point. On the other hand there 
was only small tendency among the experts toward absolute scale (60%). Nevertheless, it is 
known that HHT associated epistaxis is a swinging and variable symptom. Therefore, HHT 
patients who do not complain of epistaxis, as for instance during the period after treatment, 
could not be included in the grading system without having the zero end point. Thus, we 
found it essential that the aimed system is an absolute scale with a zero end point.  
According to this, a grading system has been designed as a proposal for an aimed system 
(Table 2). It is a multi-scale grading system, composed of three scales, which are: epistaxis 
intensity (I), epistaxis frequency (F) and the number of blood transfusions (F). This will give 
the opportunity to score the HHT patients according to their epistaxis frequency, epistaxis 
intensity, or the need of blood transfusion independently. In addition, the system can be 
converted to a single scale system which grades the epistaxis to: no bleeding, mild, moderate, 
severe, and intractable grades (as shown in paper II) by multiplying the digits corresponding 
to the frequency by the intensity and adding the blood transfusion. It focuses on a definite 
time period of observation, four weeks retrospectively. There is one absolute end point of the 
scale, which is zero. It is easy to understand for the patient when converted into five questions 
(Appendix 3). 
The grading score proposed by Hoag et al. (Table 4) for the International HHT foundation 
was discussed in paper II (84). This is an absolute and single multi-item scale, which includes 
the need of blood transfusions as a risk factor and is easy to understand for the patient. This 
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system does not focus on a definite time period. It scores the severity of HHT associated 
epistaxis according to epistaxis frequency, duration, intensity, need for transfusion, anemia, 
and aggressiveness of treatment required. The coefficient factors of these risk factors were 
calculated based on opinions of HHT patients. Eighty-nine percent of the patients in the Hoag 
study were from North America. Comparing the score with the invasiveness of treatment 
performed the external validation. The internal validation was performed through 
bootstrapping methods. It is hard to accept that a scoring system that predominantly was 
based on opinions of North American HHT patients would be generally suitable for all other 
nations. The opinions of HHT patients will probably be different, especially in respect to the 
factors as the need for blood transfusion, anemia and aggressiveness of treatment. These 
factors depend on the availability of professional health care providers and therefore depend 
on the health care system of the country. In addition, the definition of anemia as risk factor 
was not clarified. It was based on patients’ opinion on anemia, not on the hemoglobin level. 
Anemia is generally a complex issue. For the calculation of a coefficient factor for anemia it 
would be natural to use data on the hemoglobin and iron levels. On the other hand, we 
appreciate the study from Hoag and others, because it provides, for the first time, coefficient 
factors for different epistaxis related factors.    
 
6.1.3 HHT in the Norwegian population. 
This was the first study of HHT in the Norwegian population. It focused on two main aspects:  
1. The grading of HHT associated epistaxis in relation to different risk factors. 
2. The impact of HHT on different aspects of QoL. 
 
6.1.3.1 Grading of HHT associated epistaxis in the Norwegian population. 
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Paper II described the natural history of HHT associated epistaxis in the Norwegian 
population, in a cross sectional approach. The study focused on the grade of epistaxis in 
relation to risk factors like gender, age, gene mutation type and age of onset of epistaxis. The 
results were compared with the results of similar studies from other countries. The result of 
this cross sectional study could be used as a base for a future longitudinal study, concerning 
the changes in the HHT associated epistaxis with time.  
Because of the small sample size, although comparable to other published studies, it was 
important to describe and discuss all the observations even if they did not achieve statistically 
significance.  
 
Gender:  
It was observed more females than males in our study with a ratio of 1.9:1. This is comparable 
to other HHT populations in Europe and USA (1;3;11;29;55;56), but this contradicts to some 
extent the fact that HHT is an autosomal dominant (non-sex linked) disease, and the expected 
female : male ratio should be 1:1, or at least 1.1:1 since the female: male ratio in the whole 
Norwegian population is 1.1:1 (99). This deviation in the female : male ratio from the 
expected 1:1 has been mentioned in other studies concerning HHT associated epistaxis 
(1;46;88;98) and was statistically not significant in two of them (1;98), and significant in one 
study (88). A possible explanation of this deviation of the female: male ratio is the fact that 
females are usually more oriented to self health care than males, and seek health care earlier 
than males (100;101), and this makes females over represented in such studies compared to 
males. A possible explanation was that females are more severely affected by the disease than 
males, because of the chronic blood loss due menstruation, which can lead to more obvious 
symptoms and early diagnosis. Another possible explanation is the hormonal factor. It has 
been mentioned that females generally suffers milder HHT related bleeding during pregnancy 
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and during the use of estrogen-containing contraceptives, and the symptoms worsens after 
menopause (102). This can also explain the tendency of more severe grade of HHT associated 
epistaxis among females than in males (although statistically not significant in our study). 
Nevertheless, deviation of the female: male ratio in our study and previous studies may 
represent a recruitment bias.     
 
Age: 
Severe grade of epistaxis was found only among patients who were 30 years old or more and 
intractable grade could be found only among patients who were 50 years old and more. This 
finding, yet not statistically significant, gave the impression that the HHT associated epistaxis 
may be progressive with age. Similar observation has also been mentioned in other reports 
and was found to be not significant in two studies (1;55), and significant in other studies 
(3;11;88;89). This may be due to the assumption that HHT itself is progressive with age or 
aging processes, like arteriosclerosis, worsen the severity of epistaxis. However, it is a clinical 
experience that HHT associated epistaxis in elderly patients often is more severe and more 
difficult to treat. 
 
Gene mutation: 
Many studies, concerning the genotype-phenotype correlations of the HHT, have shown 
significantly higher prevalence of PAVMs (9;10;15;29-31;66;103), and CAVMs (9;15;31;66) 
in HHT1 than HHT2 subgroups of the disease. In addition, HHT1 is associated with larger 
PAVM than HHT2 (9;30). On the other hand hepatic involvements are more common in 
HHT2 than HHT1 subgroups (9;15;31). However, there is no clear difference in the 
prevalence of GI bleeding between the two subgroups of the disease (9;15;29;31;103).  
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Four of the five patients with severe grade of epistaxis in our study, and both of the patients 
with intractable grade were carrying ENG mutation. This observation, although not 
statistically significant, gave impression that there is a trend of the HHT1 to be associated 
with more severe grades of epistaxis than HHT2. Kjeldsen et al. (103) reported quite similar 
results in their 73 patient sample. Non ENG, non ALK1 carrier patients had a significantly 
lower grade of epistaxis than ENG or ALK1 carrier patients in our study. This observation has 
not been mentioned in the other studies. This finding might be of interest for future research. 
 
Age of onset: 
Seventy-seven percent of the patients started epistaxis by or before the age of 20 years and 
56% by or before the age of 10 years. This was consistent with the general agreement that 
HHT associated epistaxis starts early in life and usually is the first symptom. Assar et al. 
found that 54% of their HHT patients started epistaxis by or before the age of 10 years and 
90% before the age of 21 years (1). Forty-five percent of the patients in the Folz et al. material 
started epistaxis in childhood age, and epistaxis was the first manifestation of HHT in 93% of 
the patients (3). More than one-half of the HHT patients in the study from Reilly et al., started 
epistaxis during the first decade of life (56). Plauchu et al. described in a material of 324 
patients, that the onset of epistaxis was before the age of 20 years in 50% of the patients and 
before the age of 45 years in 90% (11).  There was no statistically significant association 
between the age of onset of epistaxis and its severity in our study. On the other hand, 
considering the gene mutation, we found that HHT1 patients started epistaxis in significantly 
earlier age than HHT2 patients (unpublished results), which is in line with many previous 
studies (9;10;29;31;103). 
 
Role of treatment: 
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There was no statistically significant difference in the grade of epistaxis between the treated 
and untreated groups. The untreated group included some patients who had been treated for 
epistaxis longer than two years before enrollment. Therefore, conclusions regarding the effect 
of the treatment on the natural history of HHT associated epistaxis would not be reliable from 
this study. Actually the term “natural history” should be referred only to those patients, who 
have not been treated for epistaxis at all throughout all their life. Such patients would 
represent mostly patients with very mild grade of epistaxis or no epistaxis at all, since it is 
expected that patients with higher grades of epistaxis have been treated previously. Including 
only patients who have not undergone treatment at all will lead firstly to a selective bias, and 
secondly to a much smaller sample size with a consequence of low statistical power. 
  
6.1.3.2 The associations between HHT and Quality of life in the Norwegian population. 
 
General consideration: 
The main findings of this study were that several HHT-disease related variables showed 
significant associations with all three levels of QoL, overall QoL (CL), mental HR-QoL 
(MCS), and physical HR-QoL (PCS) as well as disease-specific QoL (SFB-HHT-Q). HHT 
disease-related variables also explained more of the variance than demographic variables in 
all types of QoL except for the MCS. 
 
Gender: 
The difference in QoL between genders in our sample was that females had worse BP than 
males. Pasculli et al. found lower level PF, RP, RE, and SF in addition to BP, as well as lower 
levels on the PCS in women compared to men (79).  
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Associations between HHT-related variables and QoL: 
Epistaxis: 
The observations were that frequency and intensity of epistaxis are associated with reduced 
HR-QoL. However, the associations vary to different degrees with respect to different 
dimensions as Physical functioning (PF), Role physical (RP), Social functioning (SF), Role 
emotional (RE) and the physical component scale PCS. In addition, the higher level of 
intensity of nosebleeds, as well as time used to nose care, showed reduced disease-related 
QoL. This conclusion, the higher severity the poorer QoL, make sense, as well as they are in 
line with former studies (77;79;90;91). 
 
Gene mutation: 
There were no significant differences in any QoL level between HHT1 and HHT2 in our 
material. This was in concordance with our results in paper II in which no significant 
differences in the epistaxis severity could be found between ENG and ALK1 carriers. This 
agreed also with Kjeldsen et al. study from Denmark (103). Pfister and co-workers surveyed 
24 patients with identifiable mutation in either the ALK1 or ENG genes in Germany and found 
lower QoL due to PF, RP, BP, GH as well as the PCS, in patients with identifiable mutation in 
the ENG gene (104). The higher statistical power in our study, with 60 patients with an 
identifiable mutation, compared with 24 patients in Pfister et al. study, makes our results more 
statistically reliable.  
 
Number of manifestations: 
Fulfilling four Curaçao criteria was associated with lower score on GH, VT and MH of the 
HR-QoL.  In addition, having four Curaçao criteria was associated with lower overall QoL 
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(CL) score.  Fulfilling four Curaçao criteria represents a higher severity of the disease, and 
this may be a logical correlation. 
 
Pain: 
Experiencing HHT related pain was the only variable that made a statistically significant 
contribution to all levels of QoL in the multiple regression analysis. Additionally, all aspects 
of HR-QoL among patients with HHT related pain were poorer than patients without HHT 
related pain. On the other hand, the 51 patients who did not report having HHT related pain, 
showed significantly better BP, but poorer RP, GH, VT, RE and MCS than normative sample 
(unpublished data). Therefore, although pain is not a well recognized symptom of HHT, it has 
a strong negative impact on QoL when present. 
This makes pain an important aspect in considering new treatment methods of epistaxis. 
Painful methods may cause negative impact on the QoL, in spite of being objectively 
effective. 
 
Comparison to other normative samples: 
The level of HR-QoL observed in patients with HHT could be compared to Norwegian 
normative sample and samples from other studies. Lower level on all scales but BP in SF-36 
compared to the normative sample is in line with the findings in earlier studies (79;90).  
 
Comparison to other samples: 
Compared to the Italian HHT sample in the study by Pasculli et al., our patients had 
significant higher mean score on several dimensions, as well as the MCS (79). We observed a 
significantly better score in disease-related QoL in our HHT sample than reported in the 
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German sample (91). It is difficult to explain why Norwegian patients with HHT report higher 
HR-QoL and disease-specific QoL than responders from other countries. 
The level of CL in our sample of individuals with HHT was found to be similar to CL level of 
patients with other chronic diseases in our database (not published). 
 
Objective vs. subjective QoL: 
Approximately 77% of the HHT patients included in this study, reported a high level of 
overall QoL. On the other hand, taking this particular disease into account, 58% stated that the 
HHT had negative impact on their QoL, and they had poorer HR-QoL than the age- and 
gender-adjusted normative sample. The discrepancy between what they express about their 
overall QoL, ‘‘their subjective telling’’ and what they report in the HR-QoL, and the reduced 
QoL compared to normative sample, ‘‘the objective findings’’ may be due to their particular 
situation, and their use of coping strategies like acceptance and positive reinterpretation and 
growth. 
These findings underscore that the perceptions of QoL are of subjective nature, and that 
targeting non-clinical factors like coping, seems to be positively associated with QoL. In a 
systematic review of the literature on QoL in rare genetic conditions Cohen and Biesecker 
found strong correlations between QoL and psychosocial factors beyond the physical 
manifestations of the disease like coping, illness perceptions and self-esteem, demonstrating 
the importance of such factors in determining an individual’s QoL (105). They concluded that 
the individual’s adaption due to living with genetic conditions generate a gradually attain to 
restore optimal QoL. Our findings are in line with this. Even if our respondents report 
experiencing a relatively strong impact of disease-related QoL as well as poorer health-related 
QoL than the normative sample, it seems likely that they have adapted to their situation 
evidenced by their reports of good overall QoL.  
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6.1.3.3 Statistical power and the representativeness of the sample:  
 
The small samples size in paper II and III, due to the rarity of the disease and the known 
problem of underdiagnosis, caused a statistical power deficiency. We tried to improve the 
power in paper II by fusing some of the subgroups in bigger groups as done by fusing the “no 
bleeding” and “mild” in one group and the “moderate”, “severe” and “intractable” in another 
group and fusing the age groups to “<40 years”, “40-59 years” and “≥60 years”.  
Two power analyses have been performed in paper II. The first one was for the association of 
the grade of epistaxis and the gender, and the second one was for the association of grade of 
epistaxis and the age of the patient at the time of running the study. We chose these to aspects 
(age and gender) for the power analyses because these aspects showed the largest differences 
(although not significant). The power analyses showed that the sample size needed to get an 
acceptable statistical power regarding association of the grade of epistaxis and gender would 
be 883 patients and regarding the grade of epistaxis and the age would be 1032 patients. This 
is almost the total expected number of the HHT patients in Norway, which is expected to be 
about 625 – 1000 patients, considering a prevalence of HHT of 1/5000-8000 (52-54) and the 
total population in Norway of about 5 million (99). So, to get an acceptable statistical power, 
we had to include all HHT patients in Norway including undiagnosed patients, which is 
practically impossible in the national setting. Keeping in mind that the sample size needed 
regarding the other aspects like: age of onset and gene mutations is expected to be even 
higher, since the differences in these aspects were less. 
The HHT team at Oslo University Hospital-Rikshospitalet represents the only “HHT center of 
excellence” in Norway. Most patients with clinical suspicion of HHT are referred to 
Rikshospitalet from all over the country, and all patients with definite HHT diagnosis (3 or 4 
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Curacao criteria), and patients with suspected HHT diagnosis (1 or 2 criteria) with positive 
gene test for ALK1, ENG or SMAD4, and asymptomatic first degree relatives with a positive 
ENG or ALK1 gene mutation test, were registered in this data-base. The HHT data-base in 
Rikshospitalet can be considered as a representative sample of HHT population in Norway. At 
the time of running the study of paper II, there were 160 patients registered in the database, of 
which 109 patients were with definite HHT diagnosis (3 or 4 Curacao criteria). Ninety-eight 
(90%) of the 109 patients were included in paper II while 11 patients (10%) could not be 
followed up mostly because of communication difficulties. Therefore, we assume that the 
sample in paper II was representative for the HHT population in Norway at the time of 
running the study. Patients with only two diagnostic criteria with a positive gene test were not 
included in paper II. Enrolling these patients would enlarge the sample size (anyway not to 
the level of acceptable statistical power), but this would be on the expense of the possibility of 
including some patients who did not yet complete the clinical picture of the disease, and 
hence not representing the complete “natural history” of the disease. 
Power analysis has not been done in paper III. However, in spite of an even smaller sample 
size than paper II, we expect that the large control group of 990 persons lead to a better 
statistical power regarding HR-QoL.  
The lower response rate in paper III might be due to the burdens and limitations of everyday 
life experienced by HHT affected patients, but it might also be interpreted as an expression of 
their experiences of having a good life despite HHT. We had no possibility to do attrition 
analysis. On the other hand, the sample size in paper III was comparable to earlier studies in 
the area regarding HHT and QoL (79;90;91;104) and we suggest that our findings are 
representative for Norwegian HHT patients in general.  
However, we do not know the exact number of patients with HHT in Norway who have not 
been registered in the database at Rikshospitalet. 
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6.1.4 Anti-VEGF in treating HHT associated epistaxis: 
 
A wide variety of treatment options has been used for treating HHT associated epistaxis (78) 
(Table 3). All of these treatment options have some limitations and complications, and none 
of these options fit all of the patients. Therefore, new options are demanded. The new options 
should consider the other HHT associated morbidity, like pulmonary, hepatic, gastrointestinal 
and nervous system involvement.  
Understanding the genetic and molecular background of HHT opened the door for new 
treatment options. The high serum level of VEGF (51;106), identifies VEGF as a possible 
therapeutic target in HHT. 
Bevacizumab is a recombinant, humanized, monoclonal antibody that binds to and inhibits the 
biological activity of VEGF, and hence reduces endothelial cell proliferation and angiogenesis 
(93;107).  
Intravenously administered bevacizumab has been used in treating HHT associated anemia 
secondary to GI-bleeding and epistaxis, and heart failure secondary to hepatic AVM 
(74;93;108-112).  
Several groups have proposed intranasal administration of bevacizumab as a possible new 
treatment modality in HHT associated epistaxis. Davidson et al. published the first case report 
of using intranasal bevacizumab injection and spray in local anesthesia for treating HHT 
associated epistaxis, and concluded that intanasal bevacizumab could be a promising new 
treatment of HHT associated epistaxis (113). Simonds et al. treated 10 patients with KTP laser 
combined with intranasal injection of bevacizumab, and nine patients with KTP laser alone, 
and found that the combined therapy significantly decreases the frequency of nosebleed  and 
the need for blood transfusions, and improve QoL measured by work disability and social life 
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improvements (93). Karnezis et al. recently published their results of treating 32 HHT patients 
with intranasal bevacizumab, applied as either a topical spray or submucosal injection (114). 
They reported significant improvement in ESS after this treatment. The injections were done 
under general anesthesia. Chen et al. found intranasal bevacizumab is safe in treating HHT 
associated epistaxis (115).  
Paper IV describes a standardized intranasal administration of bevacizumab based on the 
anatomical vasculature of the nasal cavity (Figure 1 in paper IV). Our hypothesis was that 
injecting bevacizumab in or near the entrance points of the blood supplying vessels, could 
lead to more effective as well as more equal distribution of the drug to the whole nasal 
mucosa, thus resulting in improved therapeutic effect. Restricting the injections into four sites 
will make the procedure more suitable to be done in local anesthesia with light sedation.  
Epistaxis grades, hemoglobin levels, and QoL were used to evaluate the effectiveness of the 
treatment. Both the IFT and ESS epistaxis grading systems were used.  
Although the study design is a prospective study, the epistaxis grades were recorded 
retrospectively regarding the bleeding experience during the last four weeks before the 
treatment date, and monthly after the treatment date. This might lead to placebo effect, since 
the patient might report the last four weeks before inclusion as worse in order to be included 
in the study, and might report the four weeks after the treatment as better period believing that 
the treatment works and to please the doctor. However, the changes in IFT grades during 2-3 
years prior to inclusion into the study (Table 5) do support the value of the actual IFT grade 
during the four weeks before treatment. In addition, using the hemoglobin level as an 
objective measure in assessing the effect of the treatment, a significant improvement of the 
hemoglobin levels was in line with the improvement according in the grading scales.  
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The QoL was evaluated in three levels as in paper III; 1) Overall QoL measured by Cantril 
Ladder questionnaire; 2) Health related QoL measured by SF-36 questionnaire; and 3) 
Disease specific QoL measured by Slotosch questionnaire. 
Five of the eight patients showed significant improvement in IFT, ESS and hemoglobin levels 
after the first treatment, whereas two patients needed two doses before showing a significant 
effect. One patient showed no improvement at all even after a second treatment.  
Both patients with septal perforation (patient nr. 4 and nr.8 in table 5) responded after the first 
dose. The only patient, who had been operated with septodermoplasy (patient nr.5 in table 5), 
did not respond to the first treatment dose, but responded after the second dose. We could not 
find a reason behind the lacking response of patient nr.7. Measuring the plasma level of 
VEGF may give an explanation in the future.   
There was no significant improvement in any of the three QoL levels, four weeks after the 
treatment.   
Several studies have shown that epistaxis has the greatest impact on QoL in HHT patients 
(79;90;92;104;116-118). However, other variables including duration of illness, and the 
presence of other HHT manifestations like cerebral, pulmonary, gastrointestinal and hepatic 
involvement have significant impact on the QoL in HHT patients (79;90;104;117;119). 
Almost all the eight patients included in paper IV had other HHT complications (Table 5), and 
were among those who were most badly affected by HHT. In addition, their average QoL 
values were significantly lower than average of QoL values of the 66 HHT patients included 
in paper III (Table 6). This might influence the sensitivity of QoL measures for the 
improvement in epistaxis after the treatment, and a dramatic improvement in QoL was less 
expected. This may explain the lack of significant improvement in QoL after treatment in our 
study. On the other hand, generic QoL questionnaires have limited sensitivity, and a more 
clinically sensitive and responsive instrument for therapeutic evaluation in patients with 
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epistaxis is missing (117). Simonds et al. (93) used QoL measured by work disability and 
social life improvements to evaluate the effect of local bevacizumab treatment. Ingrand et al. 
(117) have newly introduced an epistaxis specific quality of life questionnaire as a 
complementary tool for treatment evaluation of HHT associated epistaxis.  
Only few studies used HR-QoL measured by SF-36 questionnaire to evaluate the 
effectiveness of different treatment options of HHT associated epistaxis (92;120;121).  
A variable individual sensitivity may mirror individual therapeutic resistance to bevacizumab. 
Therefore, it would be desirable for future studies to evaluate possible measures to predict the 
individual sensitivity pattern and to monitor the therapeutic response to bevacizumab. 
Monitoring the serum level of VEGF before and after the treatment with bevacizumab might 
be the first step in this evaluation.  
All the included patients had been previously treated with diode laser, pulsed dye-laser and/or 
argonplasma coagulation. Although it was not the aim of the study to compare the 
effectiveness of the previous treatment modalities with the currently described bevacizumab 
protocol, our impression is that the local therapy with bevacizumab may be of superior 
effectiveness. In this context, it is worth to mention that a single bevacizumab injection is at 
the moment more expensive (costs in Norway: 3470 NOK / 100 mg ≈500 EUR) than most of 
the other treatment modalities mentioned above, and it is unclear yet how often this treatment 
has to be repeated to gain comparable or better effect than the above mentioned methods. 
Nevertheless, this has to be further evaluated in the future.  
 
6.1.5 Limitations and difficulties of the study: 
 
1. The response rate of the experts in paper I was low (45%), a higher response rate would 
be desirable. However the expert’s opinion was not the only source of data in paper I, 
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and we do not expect dramatic changes in the properties of the aimed grading system 
with higher response rate.   
2. The chosen observation period of four weeks in the IFT grading system might be long 
enough to cause a recall bias (the patient usually remember the last week best). Using a 
daily nosebleed diary book that the patient fills prospectively might diminish this bias. 
3. The IFT grading system still needs evaluation for validation. This can be obtained by 
test-retest by different operators or by comparing the grading done by the operator with 
the grading done by the patient, using questionnaire shown in Appendix 3. It would 
also be of value to evaluate if the grading by IFT system matches with the grading done 
by other systems as done in paper IV. 
4. Paper II was a cross-section study and included patients who have been treated before. 
Therefore it is not the ideal representative of the natural history of HHT associated 
epistaxis. The ideal representative of the natural history of HHT associated epistaxis 
would be a longitudinal prospective study which follows up new HHT diagnosed 
patients 
5. Paper II and III were cross-section studies, and thereby did not allow for causal 
inferences.  
6. The rarity of the disease cause some of the subgroups in paper II and III to be small, 
which can affect the reliability of the statistical analysis and caused a power deficiency.  
7. Gen test for SMAD4 gene was not done for non ENG non ALK1 patients in paper II and 
III. 
8. Two operators did the grading of epistaxis in paper II and III. This may lead to a 
cognitive bias (a well known problem in the medical practice). Using the questionnaire 
shown in Appendix 3 could diminish this bias. In this way the patient him- or herself, 
not the operator, will grade the epistaxis. 
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9. The low response rate in paper III (71%) could be due to the burdens and limitations of 
everyday life experienced by the patients, but it might express their experiences of 
having a good life despite HHT. We had no possibility to do attrition analysis. 
10. Using different grading systems for HHT associated epistaxis, makes comparison of 
the results in of paper II and III with the results of other studies difficult and may be 
undependable.   
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Chapter 7 
 
7.1 Conclusions: 
 
7.1.1 Summary of the main results: 
 
a) A common internationally accepted grading system for HHT associated epistaxis is 
important both for research purposes and daily clinical routines in this field.  
b) There is still no common internationally accepted grading system for HHT 
associated epistaxis, and the grading system, which was proposed for the 
International HHT foundation is still not ideal. 
c)  The rarity of the disease inherently leads usually to small study samples, and 
thereby, a possible power deficiency.  
d) In the Norwegian HHT population: 
1. The incidence of HHT associated epistaxis is 97% in diagnosed patients. 
2. The majority of the patients (77%) started epistaxis by or before the age of 20 
years. 
3. The majority of the patients (90%) complained mild to moderate grade of 
epistaxis. 
4. There was no statistically significant difference in the grade of epistaxis 
between genders. 
5. There was no statistically significant difference in the grade of epistaxis 
between HHT1 type and HHT2 type of the disease. 
6. There was a statistical significant difference in the grade of epistaxis between 
non ENG, non AKL1 carrier and ENG or ALK1 carrier patients. 
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7. There was no correlation between the age of onset and the grade of epistaxis.  
8. HHT1 patients started epistaxis earlier than HHT2 patients. 
9. Higher severity of HHT associated epistaxis is significantly associated with 
lower QoL on all levels, but to different degrees with respect to different 
dimensions. 
10. Although pain is not a well-recognized symptom of HHT, it made a statistical 
significant contribution to all measures of QoL. 
11. There was no significant difference in QoL between HHT1 and HHT2 in the 
Norwegian population. 
12. The only difference in QoL between genders in the Norwegian sample was 
that females had lower bodily pain (BP) than males. 
13. HHT patients have lower HR-QoL than the normative control group. 
14. HHT patients in the Norwegian population have better score of QoL in many 
aspects than HHT patients in the Italian and German populations. 
e) Intranasal injection of bevacizumab seems to be an effective treatment for severe 
and intractable epistaxis graded according to ESS and IFT systems. 
 
7.1.2 Recommendations:  
 
1) More work to design an internationally accepted objective grading system for HHT 
associated epistaxis is required. 
2) Multicenter trials focusing on the natural history of HHT associated epistaxis and the 
impact of HHT disease generally and HHT associated epistaxis particularly on different 
aspects of QoL are required to get a larger material with statistically reliable results.     
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3) Follow up studies concerning the grades of HHT associated epistaxis, QoL in HHT 
patients and the effect of treatment over long period of time are recommended. 
4) More clinical trials are required to find the optimal dose and method of administration of 
bevacizumab in treating HHT patients. 
5) Further studies are required to evaluate possible measures to predict the individual 
sensitivity pattern and to monitor the therapeutic response to bevacizumab. Monitoring the 
serum level of VEGF before and after the treatment with bevacizumab might be the first 
step in this evaluation. 
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 Table 1: The Curaçao Criteria*(49) 
The HHT diagnosis is 
Definite if 3 criteria are present, 
Possible or suspected if 2 criteria are present, and 
Unlikely if fewer than 2 criteria are present 
Criteria 
1. Epistaxis                      spontaneous, recurrent nose bleeds 
2. Telangiectases             multiple, at characteristic sites: 
•  lips 
•  oral cavity 
•  fingers 
•  nose 
3. Visceral lesions    such as 
•  Gastrointestinal telangiectases  
          (With or without bleeding) 
•  Pulmonary AVM 
•  Hepatic AVM 
•  Cerebral AVM 
•  Spinal AVM 
4. Family history a first-degree relative with HHT according to these criteria 
 
*All offspring of an individual with HHT are at risk of having the disease since HHT may not 
manifest until late in life. If there is any concern regarding the presence of physical signs, an 
experienced physician should be consulted. Coagulation disorders should be excluded. The 
presence of visceral abnormalities in children should prompt a particularly careful check of 
other family members. These criteria are likely to be further refined as molecular diagnostic 
tests become available in the next few years. 
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Table 2: IFT epistaxis grading scale. 
 
  
Observation of intensity, frequency and blood transfusion during a period of 4 weeks. 
Intensity of the bleedings 
(I) 
Frequency of the bleedings 
(F) 
Blood transfusion 
(T) 
0 None 0 None 0 None 
1 Slight stains on the 
handkerchief 
1 1-5 times  1 Once 
2 Soaked handkerchief 2 6-10 times. 2 More than once 
3 Soaked towel 3 
 
11-29 times   
4 Bowl or similar vessel is 
necessary 
4 Daily bleeding   
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Table 3: Treatment options for HHT associated epistaxis. 
Cautery: 
 Electro  
 Chemo  
 Cryo  
 Argonplasma  
Hormonal: 
 Topical 
  Ostriol 
 Systemic 
  Tamoxifen (antiestrogen) 
  Ostradiol 
  Medoxyprogesterone  
Antifibrinolytic 
 Tranexamic acid   
 Ethamsylate  
Surgical 
  ytsalpomredotpeS 
 Closure of the nostril (Modified Young’s procedure)  
Arterial ligation: 
 Ethmoidal  (anterior & posterior) 
 Maxillary  
 External carotid 
 Sphenopalatine  
Sclerotherapy 
Selective arterial embolization 
Laser: 
  nogrA 
  PTK 
 Nd-YAG  
  edoiD 
 Pulsed-dye  
Anti-VEGF 
 Bavacizumab  
                Thalidomide 
Radiotherapy 
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Table 4: Data Sheet for the Calculation of the Epistaxis Severity Score (ESS) for 
Hereditary Hemorrhagic Telangiectasia according to Hoag et al. 
How often do you TYPICALLY have nose bleeding? (coefficient 0.14) 
0 - Less than monthly             3 - Several per week 
1 - Once per month                 4 - Once per day 
2 - Once per week                   5 - Several each day 
 
How long do your TYPICAL nose bleeds last? (coefficient 0.25) 
0 - <1 minute     3 - 16–30 minutes 
1 - 1–5 minutes                        4 - >30 minutes 
2 - 6–15 minutes 
 
 
How would you describe your TYPICAL nose bleeding intensity? (coefficient 0.25) 
0 - Not typically gushing         1 - Typically gushing or pouring 
 
Have you every sought medical attention for nose bleeding? (coefficient 0.30) 
0 - No                        1 – Yes 
 
Are you anemic (low blood count) currently? (coefficient 0.20) 
0 - No                        1 – Yes 
 
Have you ever received a red blood cell transfusion specifically because of nose 
bleeding? (coefficient 0.31) 
0 - No                        1 – Yes 
 
Six questions are answered, the number of the response is multiplied by the respective 
coefficient and the sum of these gives the raw epistaxis severity score. 
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Table 5: Indication of intranasal bevacizumab therapy among patients included in paper IV. 
Pa
tie
nt
 n
r. 
Pe
ri
od
 o
f t
re
at
m
en
t 
be
fo
re
 b
ev
ac
iz
um
ab
 
Other HHT 
manifestations Type of previous treatment Indication of bevacizumab treatment 
1 9 years  GI bleeding  Laser 
 Argon plasma 
coagulation 
 Tranexamic acid  
 IFT increase from 3 to 25 in 2 years in spite of increasing the 
frequency of laser therapy from 2/year to 4 /year. 
 Hb.around 10 in spite of Laser therapy 2-4 times /year. 
2 1 
month  
 Pulmonary 
hypertension. 
 GI bleeding. 
 Laser   Sever bleeding under laser treatment which makes the 
treatment impossible.  
 Cyclocapron and Tamoxifen are contra indicated because of 
pulmonary hypertension and valvular heart disease. 
 The patient is treated for pulmonary hypertension with 
sildenafil which aggravates the epistaxis.  
3* 
 
 
 
2 years  GI bleeding 
 Small PAVM 
(untreated)  
 Laser 
 Tranexamic acid  
 Tamoxifen 
 IFT increase from 12 to 25 in 2 years in spite of Laser therapy 
3-4 times/ year. 
 Tamoxifen had to be stopped because of side effect (vaginal 
bleeding).  
 The patient refused Septodermoplasy 
4 9 years  PAVM (treated)          Laser 
 Tranexamic acid  
 IFT increase from 8 to 15 during the last 3 years in spite of 
increasing the frequency of laser therapy from 1/year to 4/ 
year. 
 Bleeding under the laser therapy which makes the therapy 
ineffective. 
 The patient has a large septal perforation which makes the 
Septodermoplasty not promising. 
5* 20 
years 
 PAVM (treated)         Septodermoplasty 
 Laser 
 Raloxifen 
 IFT increase from 4 to 11 during the last 2 years in spite of 
increasing the frequency of laser therapy from 1/year to 2/ 
year. 
 Hb. between 10 and 11 in spite of Laser therapy 2-3 times 
/year. 
6 5 years  Hepatic AVM      Laser 
 Argon plasma 
coagulation 
 IFT increase from 3 to 9 during the last 3 years in spite of 
increasing the frequency of laser therapy from 3/year to 4/ 
year. 
 The patient refused Septodermoplasy 
7** 9 years  Migraine      Laser 
 Argon plasma 
coagulation 
 Bleeding under the laser therapy which makes the therapy 
ineffective. 
 IFT did not go under 7 during the last 3 years in spite of 
increasing the frequency of laser therapy from 3/year to 4/ 
year. 
 Hb. around 8 in spite of laser therapy 2-4 times /year. 
 The patient refused Septodermoplasy 
8 4 years  None   Laser 
 Tranexamic acid  
 IFT increase from 4 to 10 during the last 3 years in spite of 
increasing the frequency of laser therapy from 2/year to 3/ 
year. 
 Bleeding under the laser therapy which makes the therapy 
ineffective. 
 The patient has a large septal perforation which makes the 
Septodermoplasty not promising. 
* Patient did not respond to the first dose. 
** Patient did not respond to the second dose. 
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Table 6: QoL of patients in paper III and paper IV 
 Average QoL in patients included 
in paper IV (Pretreatment level) 
N = 8  
Average QoL in patients included 
in paper III  
N=66 
H
ea
lth
 r
el
at
ed
 Q
oL
, 
SF
-3
6 
Physical Functioning 60.0 75.8 
Role Physical 45.3 55.5 
Bodily Pain 71.1 71.5 
General Health 48.6 60.8 
Vitality 36.9 50.2 
Social Functioning 62.5 80.5 
Role Emotional 45.0 70.2 
Mental Health 53.5 77.8 
PCS 42.7 44.3 
MCS 40.0 50.5 
Overall QoL  7 8.5
Disease specific QoL  7.4 3.6 
P=0.002 (t-test)  
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 Table 7: The age and gender distribution of the patients with the pre-and post-
treatment epistaxis grades and hemoglobin level. 
Pa
tie
nt
 n
r. 
G
en
de
r 
A
ge
 in
 y
ea
rs
 IFT epistaxis 
grading 
Intensity 
(I) 
Frequency 
(F) 
ESS epistaxis 
grading 
Hemoglobin 
g/dl 
O
bs
er
va
tio
n 
pe
ri
od
 
(w
ee
ks
) 
Before After Before After Before After Before After Before After  
1 F 68 25 3 5 3 5 1 6.44 2.61 10.1 12.0 12 
2 M 43 12 2 7 2 5 3 5.52 1.96 11.1 14.0 10 
3 F 53 25 2 3 1 6 4 8.25 2.49 13.2 15.4 8 
4 F 36 15 4 5 3 5 3 4.70 3.02 11.7 13.4 8 
5 F 71 11 4 6 1 5 2 6.98 2.49 10.4 11.1 8 
6 M 53 9 3 5 1 4 3 4.98 2.49 11.0 17.1 10 
7 F 69 7 7 4 3 5 6 4.98 4.98 8.4 8.0 10 
8 M 59 10 3 6 1 4 3 6.20 2.49 8.5 13.0 10 
Mean 56.5 14.3 3.5 5.1 1.9 4.9 3.1 6.00 2.82 10.6 13.0 9.5 
P-value 0.007 0.02 0.01 0.001 0.01  
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The grading scales which were in use at the time of running paper I  
 
1. Grading epistaxis according to Lund et al. 
  
2. Grading epistaxis according to Reibez et al. 
Severity of epistaxis Frequency of epistaxis No. of transfusions 
Mild Few episodes / week None 
Moderate 1-2 time / day < 10/ lifetime 
Severe Daily epistaxis lasting greater than 30 min > 10/ lifetime 
  
3. Grading according to Bergler et al. 
Intensity of bleeding Frequency of bleeding 
Grade 1: slight stains on the handkerchief Grade 1: less than once a week 
Grade 2: soaked handkerchief Grade 2: a few times a week 
Grade 3: bowl or similar utensil necessary Grade 3: more than once a day 
 
4. Grading according to Pagella et al. 
Necessity of blood transfusion  
 enoN 1
 emitefil ni 01 < 2
 emitefil ni 01 > 3
Frequency of epistaxis 
 keew a ecno naht sseL 1
 keew a semit lareveS 2
 yad a semit lareveS 3
Length of epistaxis  
 nim 01 < 1
 nim 03 dna nim 01 neewteB 2
 nim 03 > 3
 
Recurrent 
epistaxis 
secondary 
to HHT 
Blood transfusion  
No blood 
transfusion 
Poor quality 
of life 
Reasonable 
quality of life 
Severe 
Moderate   
Mild 
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Expert opinion questionnaire: Grading of epistaxis in Hereditary 
Hemorrhagic Telangectesia (HHT).  
 
So far different grading systems for epistaxis in HHT exist, for example from Bergler et al1 or 
Rebeiz et al2. The aim would be a scale, which can serve as a proposal for a better grading 
system. 
 
1) Should a grading system be divided up into two scales? For example: one scale for 
frequency and another scale for severity. 
⁯ One scale (including one multi-item scale)              ⁯ More than one scale 
 
2) Ideally, should a grading system consist of a relative scale or an absolute scale? 
⁯ Relative                                  ⁯ Absolute 
 
 
 
 
3) Is the need for blood transfusion an important parameter? Mind the patient may bleed 
simultaneously from other sites than the nose. 
⁯ Yes                                        ⁯ No 
 
4) Do you think, for research purposes, a grading system should be easy to understand for 
the patient? For example when the patient is using a diary. 
⁯ Yes                                        ⁯ No 
 
5) Should a grading system focus on the duration of one single bleeding episode or 
should a grading system focus on a definite time period like for example one month 
observation time? 
⁯ Focus on one single bleeding episode        ⁯ Focus on a definite time period 
 
• Do you agree that anonymized data from this questionnaire can be used in a 
publication? 
      ⁯ Yes                                         ⁯ No 
• Do you agree that your name will be mentioned in acknowledgements of a publication 
on grading of epistaxis in HHT? 
      ⁯ Yes                                         ⁯ No 
 
• General comments: 
 
 
 
                                                            
1 Bergler W, Götte K. Hereditary hemorrhagic telangiectasias: a challenge for the clinician. Eur. Arch. 
Otorhinolaryngol. 1999; 256:10–15. 
 
2 Rebeiz EE, Bryan DJ, Ehrichman RJ, Shapshay SM . Surgical management of life threatening epistaxisin 
Osler- Weber- Rendu disease. Ann.plast.surg 1995; 35:208-213. 
Grade I mild 
Grade II moderate 
Grade III severe 
Grade O no bleeding 
Grade 1 mild 
Grade 2 moderate 
Grade 3 severe 
Grade 4 intractable 
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Questionnaire for evaluation of the severity of nosebleed associated with 
Hereditary Hemorrhagic Telangiectasia. According to IFT system  
English version 
Name: 
Date of birth: 
 It is optional answer the questionnaire. 
 Please tick next to the answer that best fits what you have experienced. 
 The questions below are for research reason. 
 Please answer all questions. 
 If you have any questions, ask your physician or call 23076202. 
 
1) During the past 4 weeks, how many times you got spot of blood from the nose or dripped a few 
drops of blood from nose? 
□ None 
□ 1-5 times 
□ 6-10 times 
□ 11 to 27 times 
□ Daily or more 
 
2) During the past 4 weeks, how many times you got blood soaked handkerchief? 
□ None 
□ 1-5 times 
□ 6-10 times 
□ 11 to 27 times 
□ Daily or more 
 
3) During the past 4 weeks, how many times you got blood soaked towel? 
□ None 
□ 1-5 times 
□ 6-10 times 
□ 11 to 27 times 
□ Daily or more 
 
4) During the past 4 weeks, low many times you got bleeding that fills so much as a bowl (1/2 liter) of 
blood? 
□ None 
□ 1-5 times 
□ 6-10 times 
□ 11 to 27 times 
□ Daily or more 
 
5) During the past 4 weeks, how many times did you get a blood transfusion? 
□None 
□ Once 
□ Several times 
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Spørreskjema for evaluering av alvorlighet av neseblødning ved 
Osler sykdom. Norwegian version 
 
 
 
 
 Det er frivillig å svare på spørreskjema. 
 Sett kryss ved det svaralternativet som passer best til det du har opplevd. 
 Spørsmålene nedenfor er kun til forskningsgrunn. 
 Vær så snill svar alle spørsmål.  
 Hvis du har spørsmål, spør behandlende lege eller ring 23076202. 
 
1) I løpet siste 4 uker, hvor mange ganger fikk du blodflekk fra nesen på lommetørkle 
eller dryppet noen dråper blod fra nesen? 
□ Ingen 
□ 6-10 ganger 
□ 11-27 ganger 
□ 11-27 ganger 
□ Daglig eller flere 
 
2) I løpet siste 4 uker, hvor mange ganger fikk du blodgjennomtrukket lommetørkle? 
□ Ingen 
□ 6-10 ganger 
□ 11-27 ganger 
□ 11-27 ganger 
□ Daglig eller fler 
 
3) I løpet siste 4 uker, hvor mange ganger fikk du blodgjennomtrukket håndkle? 
□ Ingen 
□ 6-10 ganger 
□ 11-27 ganger 
□ 11-27 ganger 
□ Daglig eller fler 
 
4) I løpet siste 4 uker, hvor mange ganger fikk du blødning som fyller så mye som en 
bolle (1/2 liter) blod? 
□ Ingen 
□ 6-10 ganger 
□ 11-27 ganger 
□ 11-27 ganger 
□ Daglig eller flere 
 
5) I løpet av siste 4 uker, hvor mange ganger fikk du blodoverføring? 
□ Ingen 
□ En gang 
□ Flere ganger 
Navn:  
Fødselsdato: 
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Symptom specific questionnaire for quality of life in patients with HHT. 
English version 
 
Dear participant, this questionnaire was developed, to collect symptoms from several diseases within the field of 
ear nose and throat. It is possible, that some questions will not be applicable in your case. Please mark “not 
applicable” in this situation. Please fill in the questionnaire completely. 
 
1. Please give three symptoms, which burdens you very much (start with the one which burdens you most).  
 
2. Please give three aspects of your life (like job, time off, working in the garden etc.) which are affected very 
much due to the disease (start with the aspect, which affects most). 
 
 
3. Please give three very important activities, which you cannot perform due to the disease (start with the most 
important). 
 
 
4. The disease has influence on my family planning. 
Yes  No  Not applicable 
 
5. Please mark the most important symptom (please only one) 
-nosebleed  
-visible red spots on the skin  
-vessel anomalies in the lung  
-vessel anomalies in the liver  
-bleeding in the gut, the fact that the disease is inherited  
-blockage of the nose, disturbances of sense of smell  
-hearing disorders  
-sinusitis  
-headaches  
-running nose  
-not applicable 
 
6. How much is your quality of life affected? 1 means no affection and 10 means highest possible affection. 
1 2 3 4 5 6 7 8 9 10 
 
7.  Which problems should be adressed in scientific research in the future? 
-development of gene therapy  
-development of new therapies for nosebleed  
-control of anomalies of vessels in internal organs  
-genetic counseling, development of early diagnostic tests 
- other: 
 
8. Which is the most bothering therapy in relation to the disease: 
-packing of the nose  
-blood transfusion  
-nasal ointment, oral iron supplements  
-tranplantation of nasal mucosa (Saunders nasoplasty) 
-laser therapy, removal of polyps as an outpatient  
-surgery of the paranasal sinuses in general anesthesia 
-not applicable. 
 
9. How much time you need to care for the nose each day. 
0-15 min,         15-30 min,           30-45 min,          45-60 min,                 more than 60 min 
 
10. How often you get treatment (each contact with a doctor) 
-more than once per month  
-every month 
-several times per year  
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-once per year  
-less than once per year  
 
11. Do you have pain and is this connected to distinct circumstances? 
(keywords) 
 
12. Which aspects have not yet been mentioned? 
(keywords) 
 
13. Repeated nosebleeds is bothering me. 
Yes  No Not applicable 
 
14. I’m worrying that I do have, apart from nosebleeds, the risk of other disorders. 
Yes No Not applicable 
 
15. How would you estimate the nose bleedings? 
Not applicable 
Intensity mild (a few drops in a handkerchief) 
moderate (soaked handkerchief) 
severe (more than one handkerchief) 
Frequency several times a day 
several times a week 
several times a months 
 
16. Imagine you would not have any nosebleeds any more. How would you estimate your quality of life on a 
scale from 1 (no affection) to 10 (highest possible affection) 
1 2 3 4 5 6 7 8 9 10 
 
17. How many times you were admitted to hospital and how many days as an in-patient you spent during the last 
12 months. 
__________ times admitted to hospital 
__________ days as in-patient 
 
18. When was the diagnosis HHT found (which year)? 
__________ 
 
 
Thank you for your cooperation ! 
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Symptomspesifikk spørreskjema for evaluering av livskvaliteten hos 
pasienter med HHT. Norwegian version 
 
1. Kan du nevne 3 symptomer av lidelsen, som påvirke deg mest (begynn med det som påvirker mest) 
 
2. Kan du nevne 3 områder av livet ditt (for eksempel yrke, fritid, hagearbeid eller lignende) som blir påvirket 
mest av lidelsen (begynn med det som påvirker mest). 
 
3. Kan du neven 3 aktiviteter, som ikke kan gjøres på grunn av lidelsen (begynn med denne aktiviteten som er 
viktigst for deg). 
 
4. Lidelsen påvirker familieplanlegging. 
- ja  - nei   - er ikke aktuelt for meg 
 
5. Sett kryss for symptomet, som påvirker deg mest (kun ett kryss) 
- neseblødning 
- synlige blodkarforandringer på huden 
- arterio-venøse malformasjoner i lunge 
- arterio-venøse malformasjoner i lever 
- blødniger fra mave-tarm trakt 
- arvelighet av lidelsen 
- nesetetthet 
- nedsatt luktesans 
- nedsatt hørsel 
- betennelse i bihulene 
- hodepine 
- forkjølelse og renning fra nese 
- ikke aktuelt for meg 
 
6. Hvor sterkt er livskvaliteten påvirket på en skala mellom 1 og 10? (1= ingen påvirkning, 10=maksimal 
påvirkning) 
 
7. Hvilket problem i sammenheng med lidelsen burde forskes på mer i fremtiden? (ikke mer enn 3 kryss) 
- genterapi 
- behandling av neseblødning 
- behandling av arterio-venøse malformasjoner i indre organer 
- genetisk veiledning 
- ny metoder for å finne sykdommen tidligere 
- annet problem: … 
 
8. Hva er den mest ubehagelige behandling for denne lidelsen? 
- nesetamponade 
- blodtransfusjon 
- nesesalve 
- operasjon med Saunders plastikk 
- laserbehandling 
- fjerning av polypper på dagkirurgisk avdeling 
- bihulekiurgi i full narkose 
- er ikke aktuelt for meg 
 
9. Hvor mye tid trenger du for å pleie nesen per dag? 
- 0-15 min - 15-30 min  - 30-45 min  - 45-60 min - mer enn 60 min 
 
10. Hvor ofte blir du behandlet for denne lidelsen? 
- oftere  - i måned - mange ganger i året  - i året  - sjeldnere 
 
11. Har du vond? Hvis ja, når? 
 
12. Hvilke aspekter av livet ditt ble ikke tatt opp i spørreskjema? 
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13. På grunn av neseblødningen føler jeg meg uvel. 
- ja  - nei  - er ikke aktuelt for meg 
 
14. Jeg er redd for at jeg muligens har andre forandringer ved siden av neseblødninger. 
- ja  - nei  - er ikke aktuelt for meg 
 
15. Hvor mye og hvor ofte blør det fra nesen? 
Intensitet:   - lite (noe dråper i et klut) 
   - moderat (hele kluten full) 
   - mye (mer enn et klut) 
Frekvens  - mange ganger om dagen 
   - mange ganger i en uke 
   - mange ganger i en måned 
 
16. Tenk du hadde ingen neseblødning lenger. Hvor ville du sette kryss på en skala mellom 1 og 10. 1=ingen 
problemer og 10=maksimale problemer 
- ikke aktuelt for meg 
- 1  - 2  - 3  - 4  - 5  - 6  - 7 
-8  - 9  - 10 
 
17. Hvor mange ganger har du vart innlagt på sykehuset på grunn av lidelsen i løpet av de siste 12 måneder? 
Hvor mange dager var du innlagt til sammen? 
…….. x innlagt 
…….. dager tilsammen 
 
18. I hvilket år ble sykdommen oppdaget hos deg? 
…….. 
 
Takk for medarbeidet! 
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